Fulcrum Equity Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-2,741
Closed -$334K 153
2025
Q4
$334K Buy
+2,741
New +$314K 0.32% 76

Other funds holding XBI

Fulcrum Equity Management's XBI Position: Q1 2026 in Review

Fulcrum Equity Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2026, closing a stake of 2,741 shares — an estimated $334K sold.

Fulcrum Equity Management first reported a position in XBI in Q4 2025 and held it in 1 quarter. The position peaked at $334K in Q4 2025. 816 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Fulcrum Equity Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2026 after selling out during the quarter.
  • Fulcrum Equity Management sold 2,741 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $334K.
  • Fulcrum Equity Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2025 and held it in 1 quarter.
  • Fulcrum Equity Management's State Street SPDR S&P Biotech ETF position peaked at $334K in Q4 2025.
  • 816 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Fulcrum Equity Management's 13F filing for Q1 2026, filed 2 Apr 2026.